Concepedia
Statistics
Publications
7
Citations
310
H-Index
Active since
2004
Affiliations
AstraZeneca (Germany)(Current)
AstraZeneca (United Kingdom)
AstraZeneca (United States)
T. A. Puchalski is an author at AstraZeneca (Germany) specializing in medicine, pharmacology, and oncology pharmacotherapy.
Publications per year
2004–2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma
Jesús F. San Miguel, Joan Bladé, Ofer Shpilberg et al. · Blood · 2014 · 141 citations · Full text
Medicine, Immunology, Oncology +16
Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors
Joachim Drevs, Michael Medinger, K. Mross et al. · Journal of Clinical Oncology · 2005 · 65 citations
Pharmacy, Pharmacokinetics, Pharmacology +14
An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
Walter Fiedler, Rolf M. Mesters, Michael Heuser et al. · Leukemia Research · 2009 · 42 citations
Medicine, Hematology, Oncology +10
Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors
Hester van Cruijsen, Emile E. Voest, Carla M.L. van Herpen et al. · Journal of Clinical Oncology · 2005 · 26 citations
Pharmacy, Pharmacology, Pharmacotherapy +15
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
Michael Medinger, K. Mross, Ute Zirrgiebel et al. · Journal of Clinical Oncology · 2004 · 14 citations
Medicine, Oncology, Pharmacology +17
1–5 of 7